Evidence map›Paper›PMID 20042498›Full record

ArticleJournal of virology2010

Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.

Jihed Chehimi, Emmanouil Papasavvas, Costin Tomescu, Bethsebah Gekonge, Shaheed Abdulhaqq, Andrea Raymond, Aidan Hancock, Kavita Vinekar, Craig Carty, Griffin Reynolds and 4 more

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Unraveled role of TLR7-mediated interferon signaling activation in COVID-19.Frontiers in cellular and infection microbiology · 2025
    Review
  5. Article
  6. Review
  7. TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.Journal of immunology (Baltimore, Md. : 1950) · 2019
    Article
  8. Article
  9. The TRAIL: TRAILshort Axis in HIV Immunopathology.Critical reviews in immunology · 2018
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jihed ChehimiThe Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Emmanouil Papasavvas
Costin Tomescu
Bethsebah Gekonge
Shaheed Abdulhaqq
Andrea Raymond
Aidan Hancock
Kavita Vinekar
Craig Carty
Griffin Reynolds
Maxwell Pistilli
Karam Mounzer
Jay Kostman
Luis J Montaner
The Wistar Institute · USUniversity of Pennsylvania · USPhiladelphia Fight · US

Funding

NK/DC Cross-Talk and Antiviral ResponseR01AI073219 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2008 to 2011
$3.0M
Antiviral activity of Peg-IFN alpha in chronic HIV-1U01AI065279 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J · 2005 to 2009
$2.8M
APCs and Innate Immunity in HIV DiseaseR01AI051225 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J. · 2002 to 2005
$1.6M
Direct/Indirect NK Activation by HIV-1 Infected CellsF32AI068405 · NIAID · WISTAR INSTITUTE · PI TOMESCU, COSTIN · 2006 to 2007
$62k
NIAID NIH HHS AI 0587780NIAID NIH HHS AI 068405NIAID NIH HHS AI 073219NIAID NIH HHS AI 51225NIAID NIH HHS F32 AI068405NIAID NIH HHS R01 AI051225NIAID NIH HHS R01 AI073219NIAID NIH HHS U01 AI065279NIAID NIH HHS UO1 AI065279
6 · The paper itself

Abstract

The function of plasmacytoid dendritic cells (PDC) in chronic human immunodeficiency virus type 1 (HIV-1) infection remains controversial with regard to its potential for sustained alpha interferon (IFN-alpha) production and induction of PDC-dependent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity of HIV-infected cells. We address these areas by a study of chronically HIV-1-infected subjects followed through antiretroviral therapy (ART) interruption and by testing PDC cytolytic function against autologous HIV-infected CD4(+) T cells. Rebound in viremia induced by therapy interruption showed a positive association between TRAIL and viral load or T-cell activation, but comparable levels of plasma IFN-alpha/beta were found in viremic ART-treated and control subjects. While PDC from HIV-infected subjects expressed less interferon regulator factor 7 (IRF-7) and produced significantly less IFN-alpha upon Toll-like receptor 7/9 (TLR7/9) engagement than controls, membrane TRAIL expression in PDC from HIV(+) subjects was increased. Moreover, no significant increase in death receptor 5 (DR5) expression was seen in CD4(+) T cells from viremic HIV(+) subjects compared to controls or following in vitro infection/exposure to infectious and noninfectious virus or exogenous IFN-alpha, respectively. Although activated PDC killed the DR5-expressing HIV-infected Sup-T1 cell line, PDC did not lyse primary autologous HIV(+) CD4(+) T cells yet could provide accessory help for NK cells in killing HIV-infected autologous CD4(+) T cells. Taken together, our data show a lack of sustained high levels of soluble IFN-alpha in chronic HIV-1 infection in vivo and document a lack of direct PDC cytolytic activity against autologous infected or uninfected CD4(+) T cells.

Indexed as

AnimalsCD4-Positive T-LymphocytesCell LineDendritic CellsFemaleHIV-1HIV InfectionsHumansInterferon-alphaInterferon Regulatory Factor-7Killer Cells, NaturalMaleReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandViral LoadViremiaInterferon-alphaInterferon Regulatory Factor-7Receptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human

Identifiers

PMID20042498
PMCPMC2826047
OpenAlexW2129042550

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.